Long-term treatment with moisturizers affects the mRNA levels of genes involved in keratinocyte differentiation and desquamation.
In a recent study, we showed that long-term treatment with two different moisturizers affected TEWL in opposite directions. Therefore, we decided to examine the effect of these moisturizers on the cellular and molecular level. In a randomized controlled study on 20 volunteers, epidermal mRNA expression of genes essential for keratinocyte differentiation and desquamation after a 7-week treatment with two moisturizers was analyzed. Treatment with one test moisturizer increased gene expression of involucrin, transglutaminase 1, kallikrein 5, and kallikrein 7, while the other moisturizer affected only expression of cyclin-dependent kinase inhibitor 1A. Thus, moisturizers are able to modify the skin barrier function and change the mRNA expression of certain epidermal genes. Since the type of influence depends on the composition of the moisturizer, these should be tailored in accordance with the requirement of the barrier of each individual patient, which merits further investigations.
Department of Medical Sciences, Dermatology and Venereology, University Hospital, 751 85 Uppsala, Sweden. izabela.buraczewska@aconordic.com
Izabela
I
Buraczewska
Berit
B
Berne
Magnus
M
Lindberg
Marie
M
Lodén
Hans
H
Törmä
D000287:Administration, Topical; D000328:Adult; D002454:Cell Differentiation / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics / Q000378:metabolism; D004311:Double-Blind Method; D000078404:Epidermal Cells; D004817:Epidermis / Q000187:drug effects / Q000378:metabolism; D005260:Female; D000091344:Filaggrin Proteins; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D006838:Hydrocarbons / Q000008:administration & dosage / Q000494:pharmacology*; D007381:Intermediate Filament Proteins / Q000235:genetics / Q000378:metabolism; D007610:Kallikreins / Q000235:genetics / Q000378:metabolism; D015603:Keratinocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D015532:Rehydration Solutions / Q000008:administration & dosage / Q000494:pharmacology*; D011503:Transglutaminases / Q000235:genetics / Q000378:metabolism
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D000091344:Filaggrin Proteins; D006838:Hydrocarbons; D007381:Intermediate Filament Proteins; D007641:Keratolytic Agents; D011498:Protein Precursors; D012333:RNA, Messenger; D015532:Rehydration Solutions; C032253:involucrin; D011503:Transglutaminases; C105804:transglutaminase 1; C400147:KLK5 protein, human; C082472:KLK7 protein, human; D007610:Kallikreins